Yahoo
NasdaqCM - Delayed Quote USD

Kiora Pharmaceuticals, Inc. (KPRX)

2.5700 -0.0500 (-1.91%)
At close: June 17 at 4:00:01 PM EDT
2.5700 0.0000 (0.00%)
Pre-Market: 7:17:36 AM EDT
Chart Range Bar
Loading chart for KPRX
  • Previous Close 2.6200
  • Open 2.5600
  • Bid 2.1000 x 300
  • Ask 3.2200 x 200
  • Day's Range 2.4900 - 2.5900
  • 52 Week Range 1.7650 - 3.2900
  • Volume 14,628
  • Avg. Volume 491,350
  • Market Cap (intraday) 11.39M
  • Beta (5Y Monthly) -0.38
  • PE Ratio (TTM) --
  • EPS (TTM) -2.7000
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.00

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

www.kiorapharma.com

13

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 6/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KPRX
30.46%
S&P 500 (^GSPC)
8.39%

1-Year Return

KPRX
12.59%
S&P 500 (^GSPC)
24.03%

3-Year Return

KPRX
63.39%
S&P 500 (^GSPC)
68.27%

5-Year Return

KPRX
99.84%
S&P 500 (^GSPC)
75.75%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings --

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-2M
-2M
-1M
-500K
0

Analyst Insights

View More

Analyst Price Targets

12.00
12.00 Average
2.5700 Current
12.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/2/2025
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 10 -> 10

Statistics

View More

Valuation Measures

Annual
As of 6/17/2026
  • Market Cap

    11.35M

  • Enterprise Value

    -2.15M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.81

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.42%

  • Return on Equity (ttm)

    -58.78%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -11.06M

  • Diluted EPS (ttm)

    -2.7000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.87M

  • Total Debt/Equity (mrq)

    2.68%

  • Levered Free Cash Flow (ttm)

    -9.52M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.5700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: